Literature DB >> 6615050

Blood cardioplegia delivery. Deleterious effects of potassium versus lidocaine.

F G Leicher, P Magrassi, P J LaRaia, W M Derkac, M J Buckley, W G Austen.   

Abstract

Delivery of cardioplegic (CP) solutions to all regions of the myocardium is critical for optimal myocardial protection during cardiac surgery. However, there are little data regarding the effects of CP agents upon coronary vascular resistance (CVR) and CP delivery. Accordingly, we evaluated blood CP (Hct 30) delivery and CVR during 75 minutes of multi-dose hypothermic blood CP arrest in an in vivo isolated dog heart preparation. Three groups of dogs were studied: K(K+ = 30 mEq/L; n = 6), L (Lidocaine = 400 mg/L; K+ = 4 mEq/L; n = 6), and KL (K+ = 30 mEq/L, Lidocaine 400 mg/L; n = 6) during total cardiopulmonary bypass and moderate systemic hypothermia (28 C). Basal CVR was calculated by measuring total coronary flow (HR 120/min; mean aortic pressure = 80 mmHg) in the empty beating heart. After aortic cross-clamping, the blood CP solution was infused into the aortic root at a constant pressure (80 mmHg) and constant temperature (16 +/- 2 C) for 60 seconds at 15 minute intervals for a total arrest time of 75 min. Total CP flow, CVR, O2 consumption, lactate extraction/production, and K+ balance during 75 minutes of arrest and 30 minutes of reperfusion were determined. The distribution of the CP solution in the left ventricle was measured with radioactive microspheres (9 +/- 1 mu). Biopsy specimens were taken to measure wet to dry ratios. Values are mean +/- SEM. Data were analyzed by BMDP-P2V. During the first CP infusion, after aortic cross-clamping, no differences in CVR or CP distribution were found among the three groups. However, CVR was increased significantly in the K group during the second CP infusion (O': 0.98 +/- 0.20 mmHg/ml/min/100 g; 15': 2.66 +/- 0.82; p less than 0.001). The CVR remained high for the remainder of the arrest period. Moreover, total, epi- and endocardial flow decreased significantly (54%, p less than 0.001). In groups L and KL, no significant changes in CVR were seen. Groups K and KL showed a significant K+ extraction during the first CP infusion. During the early reperfusion period, K+ washout occurred in these two groups, which was not seen in the L group. There was no significant difference between the three groups in myocardial O2 consumption, lactate metabolism, and water content during the arrest and the reperfusion period. In conclusion, high concentrations of K+ (30 mEq/L) can markedly increase CVR and impair blood CP delivery and distribution. These effects can be prevented by lidocaine. These findings warrant reassessment of the various additives to CP solutions and their effects on CVR and CP distribution during multi-dose hypothermic CP arrest.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6615050      PMCID: PMC1353290          DOI: 10.1097/00000658-198309000-00003

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  19 in total

1.  Effect of cardiac cooling on coronary vascular resistance in normothermic dogs.

Authors:  R A HARDIN; J B SCOTT; F J HADDY
Journal:  Am J Physiol       Date:  1960-07

2.  The importance of monitoring intramyocardial temperature during hypothermic myocardial protection.

Authors:  R C Chiu; P E Blundell; H J Scott; S Cain
Journal:  Ann Thorac Surg       Date:  1979-10       Impact factor: 4.330

3.  Effects of cardioplegic solutions on conductive coronary arteries.

Authors:  M Chiavarelli; M Toscano; R Chiavarelli; A Carpi; B Marino
Journal:  J Thorac Cardiovasc Surg       Date:  1982-07       Impact factor: 5.209

4.  The next 30 years--will the progress continue?

Authors:  R S Ross
Journal:  Circulation       Date:  1980-07       Impact factor: 29.690

5.  Some statistical methods useful in circulation research.

Authors:  S Wallenstein; C L Zucker; J L Fleiss
Journal:  Circ Res       Date:  1980-07       Impact factor: 17.367

6.  Thermographic demonstration of uneven myocardial cooling in patients with coronary lesions.

Authors:  R Ekroth; H Berggren; G Südow; J Wojciechowski; B F Zackrisson; G William-Olsson
Journal:  Ann Thorac Surg       Date:  1980-04       Impact factor: 4.330

7.  Resistance differences between blood and crystalloid cardioplegic solutions with myocardial cooling.

Authors:  M J O'Neill; N Francalancia; P D Wolf; G V Parr; J A Waldhausen
Journal:  J Surg Res       Date:  1981-04       Impact factor: 2.192

8.  Relationship between atrioventricular arrhythmias and the concentration of K+ ion in cardioplegic solution.

Authors:  R J Ellis; C Mavroudis; C Gardner; K Turley; D Ullyot; P A Ebert
Journal:  J Thorac Cardiovasc Surg       Date:  1980-10       Impact factor: 5.209

9.  Critical importance of ensuring cardioplegic delivery with coronary stenoses.

Authors:  H Becker; J Vinten-Johansen; G D Buckberg; D M Follette; J M Robertson
Journal:  J Thorac Cardiovasc Surg       Date:  1981-04       Impact factor: 5.209

Review 10.  Perioperative myocardial infarction and changes in left ventricular performance related to coronary artery bypass graft surgery.

Authors:  A J Roberts
Journal:  Ann Thorac Surg       Date:  1983-02       Impact factor: 4.330

View more
  3 in total

1.  Single-Dose Lignocaine-Based Blood Cardioplegia in Single Valve Replacement Patients.

Authors:  Jaydip Ramani; Amber Malhotra; Vivek Wadhwa; Pranav Sharma; Pankaj Garg; Malkesh Tarsaria; Himani Pandya
Journal:  Braz J Cardiovasc Surg       Date:  2017 Mar-Apr

2.  Modulation of mitochondrial bioenergetics in the isolated Guinea pig beating heart by potassium and lidocaine cardioplegia: implications for cardioprotection.

Authors:  Mohammed Aldakkak; David F Stowe; Edward J Lesnefsky; James S Heisner; Qun Chen; Amadou K S Camara
Journal:  J Cardiovasc Pharmacol       Date:  2009-10       Impact factor: 3.105

Review 3.  Hyperkalemic cardioplegia for adult and pediatric surgery: end of an era?

Authors:  Geoffrey P Dobson; Giuseppe Faggian; Francesco Onorati; Jakob Vinten-Johansen
Journal:  Front Physiol       Date:  2013-08-28       Impact factor: 4.566

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.